In this webinar you will hear from two speakers: Anthony Beckhouse on the benefits and flexibility of the NextSeq 1K/2k, and Michael Fietz on the accuracy and speed of our secondary analysis solution DRAGEN, as well as how our tertiary analysis solution Emedgene can help address bottlenecks of analysis and reporting for rare and inherited disease research. With Illumina’s exome or genome sequencing as a backbone, and the ability to do virtual panels with our tertiary solution - Emedgene. Laboratories can now create comprehensive assays to enable the latest genomic discoveries.
In this webinar you will hear from two speakers: Anthony Beckhouse on the benefits and flexibility of the NextSeq 1K/2k, and Michael Fietz on the accuracy and speed of our secondary analysis solution DRAGEN, as well as how our tertiary analysis solution Emedgene can help address bottlenecks of analysis and reporting for rare and inherited disease research. With Illumina’s exome or genome sequencing as a backbone, and the ability to do virtual panels with our tertiary solution - Emedgene. Laboratories can now create comprehensive assays to enable the latest genomic discoveries.